Business Daily from THE HINDU group of publications
Saturday, Jul 22, 2006


News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate - Overseas Investments
Corporate Results - Pharmaceuticals
Get Latest BSE Quote
Cipla looking for biotech cos in Europe, China

P. T. Jyothi Datta

Q1 profit up 53 per cent

Mumbai , July 21

Drug-maker Cipla is looking at acquisition opportunities in the biotech segment in Europe and China. The Mumbai-based company at present sits on a kitty of $170 million (Rs 762 crore), raised recently through GDRs.

Cipla is looking at biotech manufacturing opportunities in Europe and China, Cipla's Joint Managing Director, Mr Amar Lulla, told Business Line. At present, Cipla is doing its due diligence and a decision could be expected in another three months, he added.

Capacity expansion

The company is also undertaking a Rs 600-crore capacity-expansion over a two-year period, he said. Cipla's facilities at Patalganga have already been upgraded, he said. New facilities are being planned in Pune and Goa, he added.

Net rises 53 pc

Meanwhile, Cipla has posted 53 per cent growth in net-profit for first quarter ended June 30. The company has posted a net-profit of Rs 170.43 crore for the quarter under review, as compared to Rs 111.40 crore in the corresponding quarter last year. Total income (net of excise) has increased from Rs 671.17 crore in Q1 FY 05-06 to Rs 885.53 crore in Q1 FY 06-07, Cipla told the BSE.

Balanced growth

The healthy growth was on the back of balanced growth in the domestic and export markets and across all product categories, Mr Lulla said. Exports grew by 38 per cent and domestic sales grew by 20 per cent, he said. "There are pricing pressures on margins, which is why operations have to be that much more efficient," he pointed out. He expected the company to grow at 15 to 18 per cent in the forthcoming quarter.

The company also said that its Board had recommended payment of dividend of Rs 2 per equity share (face value Rs 2) on equity shares (including shares underlying GDRs and bonus shares) for the year 2005-2006.

Cipla shares were marginally up at Rs 220.15 on the BSE.

More Stories on : Overseas Investments | Pharmaceuticals | Mergers & Acquisitions | Cipla Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Praj Industries to invest in R&D


SAAG RR bags order worth Rs 3.18 crore
SEBI to focus on quality of corporate governance
R-ADAG to invest Rs 61,500 cr in Orissa
CESC shortlists BHEL, Doosan for Bengal project
Cipla looking for biotech cos in Europe, China
Exide looks for acquisition prospects in Germany
Phillips Carbon plans base outside India
Stadler Rail, Molinary Rail, Titagarh alliance eyes MRTS market
Indegene Lifesystems ties up with Johns Hopkins
Kagiso to offer radio consultancy services
Avesthagen ties up with French seeds major
Fair and Lovely scholarships
First LTU operations from Oct 1: CBEC
ITC plans Rs 15,000-cr investments
Kirloskar Bros eyes Rs 250-cr exports in 3 years
Eveready plans to unlock real estate value
Maruti looking for Indian gas conversion kit makers


The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line